Literature DB >> 3099268

Comparison of oral cephalosporins with penicillin therapy for group A streptococcal pharyngitis.

M Stillerman.   

Abstract

The purpose of the study was to compare the efficacy of cefaclor with that of penicillin V potassium (penicillin) in patients with Group A streptococcal pharyngitis. One hundred four children with pharyngitis and serologically confirmed Group A streptococci were randomly treated with cefaclor or penicillin using a mean dosage of 20 mg/kg/day for 10 days. The difference in failure rates (14% for 51 cefaclor- and 30% for 53 penicillin V-treated patients) was statistically significant (P = 0.04). In four earlier similar studies I found that cephaloglycin, cephalexin (two studies) and cefatrizine were consistently but not significantly more effective than penicillin therapy. When the data from the five studies are combined the difference between the failure rates (11% for 263 oral cephalosporin- and 23% for 230 penicillin-treated patients) becomes highly significant (P less than 0.001). The 95% confidence interval for the odds for treatment failure are 2.4 times greater for patients receiving penicillin than for those receiving one of the oral cephalosporins. On the basis of these data I conclude that the oral cephalosporins appear to be more effective than penicillin for therapy of Group A streptococcal pharyngitis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3099268     DOI: 10.1097/00006454-198611000-00010

Source DB:  PubMed          Journal:  Pediatr Infect Dis        ISSN: 0277-9730


  16 in total

1.  Epidemiology and pharmacoeconomic issues relating to acute respiratory tract infections and acute uncomplicated infections of the urinary tract.

Authors:  N M Graham
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 2.  Optimum treatment of streptococcal pharyngitis.

Authors:  F Scaglione; G Demartini; M M Arcidiacono; J P Pintucci
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group.

Authors:  K J Tack; D C Henry; W M Gooch; D N Brink; C H Keyserling
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 4.  Current guidelines for the treatment of patients with rheumatic fever.

Authors:  D Thatai; Z G Turi
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

5.  Randomized evaluation of benzathine penicillin V twice daily versus potassium penicillin V three times daily in the treatment of group A streptococcal pharyngitis. Pharyngitis Study Group.

Authors:  A Kaufhold
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

6.  Azithromycin versus cefaclor in the treatment of pediatric patients with acute group A beta-hemolytic streptococcal tonsillopharyngitis.

Authors:  J Cremer; C Wallrauch; D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

7.  Evaluation of potential factors contributing to microbiological treatment failure in Streptococcus pyogenes pharyngitis.

Authors:  S M Kuhn; J Preiksaitis; G J Tyrrel; T Jadavji; D Church; H D Davies
Journal:  Can J Infect Dis       Date:  2001-01

8.  Comparative efficacy and safety of cefprozil (BMY-28100) and cefaclor in the treatment of acute group A beta-hemolytic streptococcal pharyngitis.

Authors:  J C Christenson; E Swenson; W M Gooch; J N Herrod
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 9.  Different antibiotic treatments for group A streptococcal pharyngitis.

Authors:  Mieke L van Driel; An Im De Sutter; Hilde Habraken; Sarah Thorning; Thierry Christiaens
Journal:  Cochrane Database Syst Rev       Date:  2016-09-11

10.  Pharmacodynamic analysis and clinical trial of amoxicillin sprinkle administered once daily for 7 days compared to penicillin V potassium administered four times daily for 10 days in the treatment of tonsillopharyngitis due to Streptococcus pyogenes in children.

Authors:  M E Pichichero; J R Casey; S L Block; R Guttendorf; H Flanner; D Markowitz; S Clausen
Journal:  Antimicrob Agents Chemother       Date:  2008-03-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.